Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

BMC cancer - 20 Oct 2011

Keam Bhumsuk, Im Seock-Ah, Koh Youngil, Han Sae-Won, Oh Do-Youn, Cho Nariya, Kim Jee Hyun, Han Wonshik, Kang Keon Wook, Moon Woo Kyung, Kim Tae-You, Park In Ae, Noh Dong-Young, Chung June-Key, Bang Yung-Jue

Abstract excerpt

BACKGROUND: This study was aimed 1) to investigate the predictive value of FDG PET/CT (fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) for histopathologic response and 2) to explore the results of FDG PET/CT by molecular phenotypes of breast cancer patients who received neoadjuvant chemotherapy. METHODS: Seventy-eight stage II or III breast cancer patients who received neoadjuvant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorodeoxyglucose F18

Share to Multimodal Imaging

Share to Neoadjuvant Therapy

Share to Neoplasm Staging

Share to Positron-Emission Tomography

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 22011459
DOI: 10.1186/1471-2407-11-452
PMCID: PMC3224348

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.PMID 22011459Read ↗

Basal (18)F-FDG PET/CT as a predictive biomarker of tumor response for neoadjuvant therapy in breast cancer.Semantic proximity Read ↗

Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response.Semantic proximity Read ↗

Predicting Neoadjuvant Response of Breast Cancer at two 18F‑FDG PET/CT scanners with Radiomics model based on Combat Algorithm and Ratio FeaturesSemantic proximity Read ↗

PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer.Semantic proximity Read ↗

FDG-PET/CT and multimodal machine learning model prediction of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancerSemantic proximity Read ↗

Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.Semantic proximity Read ↗

Radiogenomics of magnetic resonance imaging and a new multi-gene classifier for predicting recurrence prognosis in estrogen receptor-positive breast cancer: A preliminary study.Semantic proximity Read ↗

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.Semantic proximity Read ↗

Mid-treatment radiologic response as an early predictor of pathologic response in TNBC in the era of pembrolizumabSemantic proximity Read ↗

MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes.Semantic proximity Read ↗

Quantitative Multiparametric MRI as an Imaging Biomarker for the Prediction of Breast Cancer Receptor Status and Molecular SubtypesSemantic proximity Read ↗

Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.